

# SA Xinyi Glass HK\$7.04 - BUY



### Timothy Lee, CFA

timothv.lee@clsa.com +852 2600 8461

### Tim Cheung

+852 2600 8588

28 February 2017

### China

### **Materials**

Reuters Bloomberg 0868.HK 868 HK

### Priced on 28 February 2017

HS CEI @ 10,298.0

12M hi/lo HK\$7.53/3.87

12M price target HK\$8.35 +19% ±% potential

**Shares in issue** 3.891.8m 43.9% Free float (est.)

US\$3,531m Market cap

### 3M average daily volume

HK\$72.7m

(US\$9.4m)

Foreign s'holding 52.3%

### **Major shareholders**

Lee Yin Yee 21.8% Tung Ching Sai 9.7%

### Stock performance (%)

ototic pe		1100 ( 11	<i>,</i>
	1M	3M	12M
Absolute	0.4	19.3	81.4
Relative	(4.4)	14.4	41.6
Abs (US\$)	0.4	0.0	81.8
8.1 <sub>7</sub> (HK\$)		(%)	<b>г</b> 250
7.0-	. d	MAN	200
5.9-	Jan Lander	مها کررو	- 150
4.8	۱۳ س	J.	- 100
3.7	hww. hy		- 50
2.6	1	-	
Mar-15		Jul-16	
_	<ul><li>Xinyi Gla</li><li>Rel to CE</li></ul>	. ,	
Source: Bloom		T (VIIO)	

www.clsa.com

# Stay optimistic

### Steady flow glass demand-supply outlook; more in Malaysia

XYG's 2016 core profit was a 2% miss on topline and tax. Meanwhile, we see nice float glass GPM expansion in 2H16 amid price hike, which we expect to stay strong amid balanced demand/supply with higher cost. New expansion in Malaysia is also a support to margin given lower fuel costs there. We retain BUY on XYG given undemanding valuation of 7.4x 17CL PE/6.6% 17CL dividend yield, with stable float glass demand/ supply dynamics (eg, less worry on property, supply limitation amid pollution controls) and any cost reductions as key catalysts.

### 2016 core profit 2% miss on revenue

2016 core profit (HK\$3,055m, +76.2% YoY) is a 2.0% miss to CL. This is mainly due to a 3.7% miss in revenue (+12.1% YoY) for all segments (auto, construction, and float glasses) and higher-than-expected tax, offset by lower-than-expected OPEX. Meanwhile, GPM was in line, with float glass GPM expanding 16.4ppt YoY (to 27.5%) amid lower cost and ASP hike in 2H16.

### Stable float demand/supply in 17CL

We reiterate our view of a relatively balanced float glass demand/supply in 17CL, instead of a deteriorating market: for demand, property restrictions are more focused in specific regions; and for supply, further restart/brand new capacity are limited from here, with stricter pollution controls and higher industry self-discipline to help. Float glass prices also stayed high even under slack season since 4Q16, with higher costs/better-than-expected demand providing support, and new Malaysia plant will support margin as well. We forecast float glass GPM of 30.9% in 17CL, vs 22.3%/31.2% in 1H16/2H16.

### **Further expansions**

Total Capex budget for 2017 is HK\$2.5bn (2016: HK\$1.85bn), mainly for Malaysia's expansion and investment property at Qianhai. In particular, with the expected good profitability in Malaysia, XYG will invest the second phase with two float glass lines. XYG will further improve efficiency of auto glass and construction glass facilities despite no/limited capacity growth, which will help support steady sales performance despite impact from Rmb depreciation.

### **Reiterate BUY**

We lift our 17/18CL core profit forecasts by 3.6%/4.5% mainly on higher float glass GPM and capacity, partly offset by lower contributions from XYS. Our TP is unchanged at HK\$8.35, which is based on blended PE/PB approach.

### **Financials**

Year to 31 December	15A	16A	17CL	18CL	19CL
Revenue (HK\$m)	11,460	12,848	13,744	14,581	15,196
Rev forecast change (%)	-	-	(0.8)	1.6	-
Adjusted net profit (HK\$m)	1,734	3,055	3,758	4,181	4,568
NP forecast change (%)	-	-	3.6	4.5	-
Adjusted EPS (HK¢)	43.0	76.5	93.9	104.4	114.1
CL/consensus (9) (EPS%)	-	-	104	107	165
Adj EPS growth (% YoY)	51.7	77.8	22.7	11.2	9.3
Adjusted PE (x)	16.4	9.2	7.5	6.7	6.2
Dividend yield (%)	3.8	5.7	6.6	7.4	8.1
ROE (%)	16.9	24.8	26.6	25.8	24.7
Net debt/equity (%)	37.2	37.0	30.7	17.8	6.2

Source: CLSA



XYG FY16 core profit missed by 2%, due to 3.7% miss in revenue and higher-than-expected tax

# 2016 core profit 2% miss on revenue

XYG reported 2016 results with reported net profit (HK\$3,213m, +52.1% YoY) 2% above Bloomberg, but core profit (HK\$3,055m, +76.2% YoY) a 2.0% miss to CL. This is mainly due to a 3.7% miss in revenue (+12.1% YoY) for all segments (auto, construction, and float glasses) and higher-than-expected tax, offset by lower-than-expected OPEX. Meanwhile, GPM was in line, with float glass GPM expanded 16.4ppt YoY (to 36.3%) amid lower cost and ASP hike in 2H16.

### **Key highlights:**

All segment logged slightly lower than expected revenue

GPM was helped by lower cost

Tax expense is higher than expected

Core profit is 2.0% below our forecast; reported profit is in line with previous profit alert

- Reported revenue was HK\$12,848m, up 12.1% YoY and 3.7% below our forecast. All segments logged slightly lower than expected revenue, including auto glass sales (-1.0% YoY, 5.8% miss), construction glass sales (-2.3% YoY, 3.7% miss) and float glass sales (+29.6% YoY, 2.0% miss), which is likely partly related to Rmb depreciation.
- ➤ Reported GPM was in-line, at 36.3%, +8.9ppt YoY. In particular, GPM for float glass was 27.5%, +16.4ppt YoY and 0.8ppt above us, thanks to NG price cut announced in Nov-16 to lower fuel cost, as well as significant ASP hike in 2H16. GPM for auto glass and construction glass also expanded on lower cost.
- ➤ OPEX was HK\$1,793m (+13.2% YoY), 2.8% below our forecasts, suggesting slightly better than expected efficiency despite the preoperating expenses for the new Malaysia plant. Depreciation expense was HK\$797m (+4.4% YoY), also below our forecast by 6.9%.
- > Share of associate profit was HK\$563m, up 77.3% YoY and 2.4% above us, due to significant increase in profit contribution from XYS.
- Meanwhile, tax expense was HK\$607m (+128.3% YoY), 14.1% above us given certain subsidiaries yet to enjoy preferential tax rates from being recognised as high-tech enterprises which are under applications.
- ➢ Reported net profit was up 52.1% YoY to HK\$3,213 m, in line with the previous profit alert (HK\$2,958-3,275m), and 2.4% above Bloomberg (HK\$3,139m). After adjusting for FX and fair value gains and last year's non-core items (FX, subsidiary disposal, deemed gain from XYS's placement), core profit was calculated to be HK\$3,055m, up 76.2% YoY and 2.0% below our forecast.
- ➤ The company declared a final dividend of 23.0 cents per share, implying full-year payout ratio of 48%.



Figure 1

XYG FY16 earnings summary							
HKD m	FY15A	FY16A	YoY growth	FY16CL	Forecast vs actual	1H16	2H16
Sales	11,460	12,848	12.1%	13,348	(3.7%)	5,885	6,963
COGS (excl depr)	(7,564)	(7,392)	(2.3%)	(7,658)	(3.5%)	(3,455)	(3,937)
Operating expenses (ex D&A)	(1,583)	(1,793)	13.2%	(1,844)	(2.8%)	(848)	(944)
Opex %	13.8%	14.0%	1.0%	13.8%	1.0%	14.4%	13.6%
Core Ebitda	2,313	3,664	58.4%	3,846	(4.7%)	1,582	2,082
Depreciation	(763)	(797)	4.4%	(857)	(6.9%)	(389)	(408)
Core Ebita	1,550	2,867	85.0%	2,989	(4.1%)	1,193	1,674
Amortisation	(32)	(30)	(5.7%)	(31)	(3.4%)	(15)	(15)
Core Ebit	1,518	2,837	86.9%	2,958	(4.1%)	1,178	1,659
Ebit Margin	13.2%	22.1%		22.2%		20.0%	23.8%
Other revenue (ex interest exp)	215	342	58.9%	208	64.3%	104	238
Interest Income	40	51	27.1%	53	(3.7%)	16	35
Interest Expense	(90)	(128)	41.5%	(118)	8.0%	(60)	(67)
Net Interest Expense	(50)	(77)	53.0%	(65)	17.5%	(44)	(33)
Share of Associate Profit	317	563	77.3%	549	2.4%	312	250
Profit Before Tax	2,000	3,665	83.2%	3,650	0.4%	1,550	2,115
Tax Expense	(266)	(607)	128.3%	(532)	14.1%	(202)	(405)
Minority Interest	0	(3)	499.8%	0	499.8%	0	(2)
Net Profit After Tax, pre Exceptionals	1,734	3,055	76.2%	3,117	(2.0%)	1,347	1,707
Exceptional gain/(loss)	379	159	(58.1%)	0	NA	22	137
Net Profit After Tax	2,113	3,213	52.1%	3,117	3.1%	1,369	1,844
NPM, pre-exceptional	15.1%	23.8%		23.4%		22.9%	24.5%
Key operating statistics							
Sales (HKD m)							
Automobile glass products	3,787	3,748	(1.0%)	3,978	(5.8%)	1,990	1,758
Construction glass	2,651	2,590	(2.3%)	2,691	(3.7%)	1,220	1,370
Float glass	5,022	6,510	29.6%	6,643	(2.0%)	2,675	3,835
Wind farm		-	NA	37	(100.0%)		
Total	11,460	12,848	12.1%	13,348	(3.7%)	5,885	6,963
Gross profit (HKD m)							
Automobile glass products	1,679	1,836	9.3%	1,955	(6.1%)	837	867
Construction glass	898	1,032	15.0%	1,081	(4.5%)	383	556
Float glass	556	1,791	222.3%	1,771	1.1%	190	1,195
Wind farm		-	NA	26	(100.0%)		
Total	3,133	4,659	48.7%	4,833	(3.6%)	1,410	2,618
Gross margin							
Automobile glass products	44.3%	49.0%	4.6 ppt	49.1%	-0.2 ppt	48.7%	49.3%
Construction glass	33.9%	39.9%	6 ppt	40.2%	-0.3 ppt	39.0%	40.6%
Float glass	11.1%	27.5%	16.4 ppt	26.7%	0.8 ppt	22.3%	31.2%
Wind farm			NA	70.3%	NA		
Overall	27.3%	36.3%	8.9 ppt	36.2%	0.1 ppt	24.0%	37.6%

Source: Company, CLSA



Reiterate our view of a relatively balanced float glass demand/supply in 17Cl

Raising float glass GPM forecasts given prices stayed high

Float glass prices stayed high even under slack season

# Stable float demand/supply in 17CL

We reiterate our view of a relatively balanced float glass demand/supply in 17CL, instead of a deteriorating market. For demand, property restrictions are more focused in specific regions, instead of nationwide tightening. Our property team holds the view that there is low risk of the tightening measures becoming too aggressive as there are no pressing affordability issues, as price increases have happened mostly in cities of high wealth/income/population growth where affordability should catch up. For supply, our previous channel checks suggested further restart/brand new capacity are limited from here, particularly that environmental standards are becoming stricter and stricter.

Besides, we also noted float glass prices stayed high in 4Q16 and early 2017 despite the traditional slack season. Increased costs are supporting factors to prices, and we also believe market demand is also fairly decent to help. In addition to the increase in natural gas price during winter, soda ash prices surged significantly since 4Q16, which would result in higher cost in 17CL despite we do not see these as long lasting. Imported, lower-priced soda ash as well as new plant in Malaysia (with lower NG cost) will support margin as well. We forecast float glass GPM of 30.9% in 17CL (from 27.9% previously), vs 22.3%/31.2% in 1H16/2H16.

ire 2



Source: WIND, CLSA

igure 3




Source: SCI99.com, CLSA



# We expect fairly stable demand/supply dynamics in 2017

igure 4



Source: CLSA

Figure 5

Float glass capacity under operation in China (including lines just ignited and ultra-clear lines)



Source: WIND, CLSA

Figure 6

### **Domestic soda ash prices**



Source: WIND, CLSA

### More supply discipline

The China Architectural and Industrial Glass Association proposed last year to setup a fund to subsidise elimination of excess capacity in the float glass industry. They are proposing a surcharge of c.Rmb0.052/kWh for each unit of electricity used for all glass capacity in China for 5 consecutive years, or Rmb0.26/kWh for 1 year. The fund collected will be used for compensation for shutting down glass capacity on the basis of Rmb10/weight case. The proposal would be submitted for government studying.

Glass industry is not yet on the top of the government's supply side reform agenda, probably due to the relatively larger no. of private companies in the industry but less SOEs, which also implies low market concentration. Supply has been mainly controlled by: 1) Pollution controls, e.g. some outdated capacity was asked to stop production in late 4Q16 in northern China; and, more importantly, 2) Industry discipline. Glass production lines have to run 24x7 once started operation, thus producers can only cut prices to reduce inventory when demand is not good. If demand/price is too weak to support profitability, producer will choose to shut down operation which takes at least 6-9 months to resume operation which is also very costly.




The surcharge proposal is not completely new to the materials industry, but we believe execution is the key, given the bulk of small private players in the industry. The incremental cost is roughly c.7-8% above current tariff, or <1% of overall glass production cost, thus we believe this will not face a lot of pushback from large producers but still could likely have some oppositions from small players. Although XYG's management disagrees with this surcharge plan, overall we believe this implies a relatively positive industry supply outlook for the whole industry, which is also supported by stricter pollution controls which may trigger occasional distortion to market supply.

Reiterate our view of a relatively balanced float glass demand/supply in

### **Further expansions**


Total Capex budget for 2017 is HK\$2.5bn (2016: HK\$1.85bn), mainly for Malaysia's expansion and investment property at Qianhai. In particular, the first phase project in Malaysia started operation in Jan-2017. With the expected good profitability, XYG will invest the second phase with two float glass lines (2,000t/d in total) expected to commence operation by 2Q18. Besides, XYG will also further improve operating efficiency of auto glass and construction glass facilities despite no/limited capacity growth, which will help support steady sales performance despite impact from Rmb depreciation.

Figure 7




Source: Company, CLSA

Figure 9




Source: Company, CLSA

Figure 8



Source: Company, CLSA

Figure 10



Source: Company, CLSA



### **Lifting forecasts**

### **Reiterate BUY**

We lift our 17/18CL core profit forecasts by 3.6%/4.5% mainly on higher float glass GPM and capacity, partly offset by lower profit contributions from Xinyi Solar (XYS). We also roll forward our valuation base year: For PE we use a target multiple of 9x on 18CL EPS (from 10x on avg 17-18CL); for PB we use a target multiple of 1.9x on 17CL BVPS (from avg 16-17CL). Our TP is thus unchanged at HK\$8.35. Retain BUY on undemanding valuation of 7.4x 17CL PE/6.6% 17CL dividend yield, with stable float glass demand/supply dynamics (e.g. less worry on property sector, supply limitation amid pollution controls) and any cost reductions (eg, natural gas, soda ash) as key catalysts.

Figure 1:

Earnings revisions						
_		17CL			18CL	
_	New	Old	Change	New	Old	Change
Revenue (HK\$ m)	13,744	13,854	-0.8%	14,581	14,352	1.6%
- Automobile glass products	3,794	4,060	-6.5%	3,827	4,194	-8.7%
- Construction glass	2,435	2,583	-5.7%	2,398	2,544	-5.7%
- Float glass (inc. electronic glass)	7,304	7,006	4.3%	8,005	7,273	10.1%
- Wind farm	210	204	2.8%	350	340	2.8%
Gross profit margin	39.0%	37.8%	1.1 ppt	39.6%	38.2%	1.4 ppt
- Automobile glass products	52.4%	52.0%	0.4 ppt	52.0%	51.2%	0.8 ppt
- Construction glass	39.6%	39.9%	-0.2 ppt	38.6%	38.4%	0.1 ppt
- Float glass (inc. electronic glass)	30.9%	27.9%	2.9 ppt	32.6%	29.1%	3.5 ppt
- Wind farm	70.3%	70.3%	0.0 ppt	70.3%	70.3%	0.0 ppt
Core profit (HK\$ m)	3,758	3,627	3.6%	4,181	4,003	4.5%

Source: CLSA

Figure 12

Our TP is based on a blended PE and PB approach

Valuation of Xinyi Glass	
PE basis	
Average 17-18CL EPS (HK\$)	1.05
Target multiple (x)	9.0
Fair value (HK\$)	9.50
PB basis	
Average 16-17CL BVPS (HK\$)	3.78
Target multiple (x)	1.9
Fair value (HK\$)	7.20
Average (HK\$)	8 35

Source: CLSA

Implying 17/18CL PE

Figure 13

Current market-cap implies 7.0x/6.3x its non-solar businesses earnings in 17/18CL

Valuation of Xinyi Glass's non-solar busin	ess		
HK\$m		FY17CL	FY18CL
Net profit of Xinyi Glass		3,758	4,182
Less: after-tax share of profits of Xinyi Solar		(612)	(687)
Non-solar profit	(a)	3,146	3,494
Current market cap of Xinyi Glass	(b)	27,406	27,406
Current market cap of Xinyi Solar	(c)	18,424	18,424
M'cap of Xinyi Glass's non-solar business	(d) = (b) - 29.5%*(c)	21,965	21,965
PE of Xinyi Glass's non-solar business	(e) = (d)/(a)	7.0	6.3
Source: CLSA			

**28 February 2017** 

8.8x/7.9x



Figure 14






Figure 15



Source: CLSA, Datastream

Figure 16



Source: CLSA, Datastream



Figure 17

### Valuation comp - Xinyi Glass

an al		Price	Mkt Cap	ADTV		CLSA			12m forv	ward val	uations		EPS Cagr	PEG	Gearing	Per	forma	ance	(%)
Stock	Ticker	(local)	(USD,m)	(USD,m)	Rec	Target	Upside	PE	РВ	Yield	EV/Ebitda	ROE	FY1-FY3	PEG	(%)	1m	3m	6m	12m
Xinyi Glass	868 HK	7.04	3,531	9.4	BUY	8.35	19%								37	0	22	5	92
Fuyao Glass - H	3606 HK	24.20	7,274	6.6				15.3	2.7	4.2	8.8	18.3	10.1	1.5	4	5	3	19	57
China Glass	3300 HK	0.90	210	0.1											47	7	0	(18)	11
Luoyang Glass	1108 HK	5.71	388	1.1											221	9	2	23	36
CSG Holding	000012 CH	11.63	2,806	72.3				23.3							65	2	(16)	(4)	21
Fuyao Glass - A	600660 CH	19.54	7,274	36.8				14.2	2.5	4.4	8.8	18.2	9.2	1.5	4	4	3	19	49
Yaohua Pilkington	600819 CH	9.08	1,129	19.3											46	10	21	15	52
Shandong Jinjing	600586 CH	4.87	1,034	13.4				9.9	1.5		9.3	7.4	3.4	2.9	57	6	4	4	24
AVIC Sanxin	002163 CH	10.24	1,198	62.4											265	10	20	29	49
Xiuqiang Glasswork	300160 CH	13.00	1,131	17.3				41.4	3.0		26.5	12.1	40.9	1.0	1	14	(2)	(3)	29
Changzhou Almaden	002623 CH	37.51	874	27.3											(7)	2	(21)	7	27
Zhuzhou Kibing	601636 CH	4.44	1,686	24.4				15.5	1.7		7.0	11.8	15.9	1.0	82	5	5	9	30
Taiwan Glass	1802 TT	17.55	1,665	2.5				43.9	1.1			3.1			67	33	30	35	37
Asahi Glass	5201 JP	918.00	9,694	40.6	BUY	1,025	12%								25	9	24	40	68
Nippon Sheet Glass	5202 JP	844.00	679	11.3				10.3	0.9	0.4	6.6	8.3	30.4	0.3	333	(9)	5	6	17
Central Glass	4044 JP	513.00	981	5.2				10.8	0.6	2.1	5.9	5.4	4.9	2.2	23	(5)	13	30	(20)
Hankuk Glass Industries	002000 KS	27,750.00	248	0.0											(16)	3	1	1	14
Cie de St-Gobain	SGO FP	45.25	26,631	70.6				15.7	1.2	2.9	7.1	8.0	13.5	1.2	29	(1)	11	15	26
PPG Industries Inc	PPG US	102.45	26,339	157.2				16.2	5.4	1.6	10.6	34.5	9.6	1.7	52	2	7	(3)	6
Turkiye Sise	SISE TI	3.93	2,232	4.7				10.4	0.9	3.0	6.2	10.0	14.1	0.7	15	(3)	18	15	25
Trakya Cam Sanayii	TRKCM TI	3.00	773	1.7				9.1	0.8	5.8	6.8	9.3	(18.0)		14	(3)	7	20	74
Corning	GLW US	27.65	25,662	186.6				16.3	1.7	2.2	8.1	10.3	6.6	2.5	(8)	4	15	22	51
Average	•	•		•		·	•	18.0	1.9	3.0	9.3	12.0	11.7	1.5	61.5	,			

Source: Bloomberg, CLSA

### **Valuation details**

We value XYG using a blended PE and PB approach. We apply a target multiple of 9x to 18CL EPS and a target multiple of 1.9x to 17CL BVPS, in line with the historical averages.

### **Investment risks**

Key risks include: 1) Weakening of the property market or even the auto market. Demand for float glass and construction glass is highly dependent on the property market. Besides, despite being a stable business, the auto glass segment is correlated to the global number of vehicles in use, and any significant slowdown in the global auto industry may also affect the segment's performance. 2) Further tightening of credit. Tightening of credit also affects developers' cash flows and progress in construction of property projects. 3) Incremental production costs. A significant surge in natural gas, international crude oil prices and other raw material costs may affect XYG's gross margin if it cannot pass on incremental costs by raising ASP. 4) More capacity additions in the market.

### Valuation details - Asahi Glass Co Ltd 5201 JP

We value the stock using a PE valuation methodology as the company's earnings trends has brightened as chemicals and flat glass earnings growth offsets LCD weakness. We forecast Asahi Glass to see revenue and operating profit growth in the medium term as the US and Eurozone economies improve and chemicals experience success with new products along with growth in Southeast Asia. Our target price of \$1,025 is based on a PE of 18x, which is the three-year average, FY12/18CL estimates.



### Investment risks - Asahi Glass Co Ltd 5201 JP

Fluctuating fuel costs are a risk because almost all of its businesses consume large amounts of fuel and materials. A US\$1 fall in oil prices adds ¥400mn to OP. An increase in oil prices would cause a decline in profits profits. We expect the LCD substrate market to continue to see price cuts, but if weakness in downstream markets put more pressure on prices they may decline more than our expectations. The company is expecting ¥30bn in non-operating costs, but we are assuming ¥20bn. If non-operating costs reach ¥30bn, net profits would drop which would affect our PB-ROE correlation derived PB multiple.





	Summary fin	anciais				
	Year to 31 December	2015A	2016A	2017CL	2018CL	2019CL
	Summary P&L forecast (Hk	(\$m)				
	Revenue	11,460	12,848	13,744	14,581	15,196
	Op Ebitda	2,313	3,664	4,392	4,897	5,277
**************************************	Op Ebit	1,518	2,837	3,485	3,890	4,194
Improving margins and	Interest income	40	51	48	28	30
higher associates profit to drive earnings growth	Interest expense	(90)	(128)	(90)	(73)	(38)
drive earnings growth	Other items	912	1,063	969	1,061	1,168
	Profit before tax	2,380	3,823	4,412	4,906	5,354
	Taxation	(266)	(607)	(651)	(722)	(782)
	Minorities/Pref divs	0	(3)	(3)	(3)	(3)
	Net profit	2,113	3,213	3,758	4,181	4,569
	Summary cashflow forecast	(HK\$m)				
	Operating profit	1,518	2,837	3,485	3,890	4,194
	Operating adjustments	-	-	_	_	_
	Depreciation/amortisation	795	827	906	1,008	1,083
	Working capital changes	(207)	(426)	(109)	(93)	(68)
	Net interest/taxes/other	(421)	(784)	(741)	(795)	(820)
Canary mainly an usind	Net operating cashflow	1,685	2,453	3,541	4,010	4,389
Capex mainly on wind farm and Malaysia	Capital expenditure	(1,967)	(1,853)	(2,500)	(1,500)	(1,500)
-	Free cashflow	(282)	600	1,041	2,510	2,889
investments	Acq/inv/disposals	-	-	-	-	-
	Int, invt & associate div	951	1,112	1,014	1,086	1,195
	Net investing cashflow	(1,016)	(741)	(1,486)	(414)	(305)
	Increase in loans	16	1,646	(1,907)	(1,508)	(1,827)
	Dividends	(1,029)	(1,622)	(1,817)	(2,021)	(2,208)
	Net equity raised/other	812	(267)	0	0	-
	Net financing cashflow	(202)	(244)	(3,724)	(3,529)	(4,035)
	Incr/(decr) in net cash	468	1,468	(1,669)	67	49
	Exch rate movements	-	-	-	-	-
	Opening cash	832	1,300	2,768	1,099	1,166
	Closing cash	1,300	2,768	1,099	1,166	1,216
	Closing cash Summary balance sheet for	•	•	1,099	1,166	1,216
Balance sheet still healthy	_	•	•	<b>1,099</b>	<b>1,166</b>	<b>1,216</b>
Balance sheet still healthy	Summary balance sheet for	ecast (HK\$m)	·	·	ŕ	
Balance sheet still healthy	Summary balance sheet for Cash & equivalents	ecast (HK\$m) 1,300	2,768	1,099	1,166	1,216
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors	ecast (HK\$m) 1,300 1,136	2,768 1,036	1,099 1,162	1,166 1,233	1,216 1,285
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories	ecast (HK\$m) 1,300 1,136 1,223	2,768 1,036 1,321	1,099 1,162 1,292	1,166 1,233 1,347	1,216 1,285 1,387
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets	1,300 1,136 1,223 1,337	2,768 1,036 1,321 1,412	1,099 1,162 1,292 1,412	1,166 1,233 1,347 1,412	1,216 1,285 1,387 1,412 14,419 1,108
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets	1,300 1,136 1,223 1,337 11,971	2,768 1,036 1,321 1,412 11,831 1,193 4,462	1,099 1,162 1,292 1,412 13,453 1,164 4,462	1,166 1,233 1,347 1,412 13,974 1,135 4,462	1,216 1,285 1,387 1,412 14,419 1,108 4,462
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets	1,300 1,136 1,223 1,337 11,971 1,281 3,174 21,422	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b>	1,099 1,162 1,292 1,412 13,453 1,164 4,462 <b>24,044</b>	1,166 1,233 1,347 1,412 13,974 1,135 4,462 <b>24,729</b>	1,216 1,285 1,387 1,412 14,419 1,108 4,462 <b>25,287</b>
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt	1,300 1,136 1,223 1,337 11,971 1,281 3,174 21,422 2,514	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165	1,099 1,162 1,292 1,412 13,453 1,164 4,462 <b>24,044</b> 2,379	1,166 1,233 1,347 1,412 13,974 1,135 4,462 <b>24,729</b> 1,757	1,216 1,285 1,387 1,412 14,419 1,108 4,462 <b>25,287</b> 1,003
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors	1,300 1,136 1,223 1,337 11,971 1,281 3,174 21,422 2,514 740	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789	1,099 1,162 1,292 1,412 13,453 1,164 4,462 <b>24,044</b> 2,379 777	1,166 1,233 1,347 1,412 13,974 1,135 4,462 <b>24,729</b> 1,757 810	1,216 1,285 1,387 1,412 14,419 1,108 4,462 <b>25,287</b> 1,003 834
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs	1,300 1,136 1,223 1,337 11,971 1,281 3,174 21,422 2,514 740 1,705	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046	1,099 1,162 1,292 1,412 13,453 1,164 4,462 <b>24,044</b> 2,379 777 2,046	1,166 1,233 1,347 1,412 13,974 1,135 4,462 <b>24,729</b> 1,757 810 2,046	1,216 1,285 1,387 1,412 14,419 1,108 4,462 <b>25,287</b> 1,003 834 2,046
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs	1,300 1,136 1,223 1,337 11,971 1,281 3,174 21,422 2,514 740 1,705 3,514	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509	1,099 1,162 1,292 1,412 13,453 1,164 4,462 <b>24,044</b> 2,379 777 2,046 3,389	1,166 1,233 1,347 1,412 13,974 1,135 4,462 <b>24,729</b> 1,757 810 2,046 2,503	1,216 1,285 1,387 1,412 14,419 1,108 4,462 25,287 1,003 834 2,046 1,429
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs	ecast (HK\$m) 1,300 1,136 1,223 1,337 11,971 1,281 3,174 21,422 2,514 740 1,705 3,514 223	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 266	1,099 1,162 1,292 1,412 13,453 1,164 4,462 24,044 2,379 777 2,046 3,389 266	1,166 1,233 1,347 1,412 13,974 1,135 4,462 24,729 1,757 810 2,046 2,503 266	1,216 1,285 1,387 1,412 14,419 1,108 4,462 25,287 1,003 834 2,046 1,429 266
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity	ecast (HK\$m) 1,300 1,136 1,223 1,337 11,971 1,281 3,174 21,422 2,514 740 1,705 3,514 223 7	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 266 66	1,099 1,162 1,292 1,412 13,453 1,164 4,462 24,044 2,379 777 2,046 3,389 266 66	1,166 1,233 1,347 1,412 13,974 1,135 4,462 24,729 1,757 810 2,046 2,503 266 66	1,216 1,285 1,387 1,412 14,419 1,108 4,462 25,287 1,003 834 2,046 1,429 266 66
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds	ecast (HK\$m) 1,300 1,136 1,223 1,337 11,971 1,281 3,174 21,422 2,514 740 1,705 3,514 223 7 12,718	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 266 66 13,181	1,099 1,162 1,292 1,412 13,453 1,164 4,462 24,044 2,379 777 2,046 3,389 266 66 15,122	1,166 1,233 1,347 1,412 13,974 1,135 4,462 24,729 1,757 810 2,046 2,503 266 66 17,282	1,216 1,285 1,387 1,412 14,419 1,108 4,462 25,287 1,003 834 2,046 1,429 266 66 19,643
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity	ecast (HK\$m) 1,300 1,136 1,223 1,337 11,971 1,281 3,174 21,422 2,514 740 1,705 3,514 223 7	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 266 66	1,099 1,162 1,292 1,412 13,453 1,164 4,462 24,044 2,379 777 2,046 3,389 266 66	1,166 1,233 1,347 1,412 13,974 1,135 4,462 24,729 1,757 810 2,046 2,503 266 66	1,216 1,285 1,387 1,412 14,419 1,108 4,462 25,287 1,003 834 2,046 1,429 266 66
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds	ecast (HK\$m) 1,300 1,136 1,223 1,337 11,971 1,281 3,174 21,422 2,514 740 1,705 3,514 223 7 12,718	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 266 66 13,181	1,099 1,162 1,292 1,412 13,453 1,164 4,462 24,044 2,379 777 2,046 3,389 266 66 15,122	1,166 1,233 1,347 1,412 13,974 1,135 4,462 24,729 1,757 810 2,046 2,503 266 66 17,282	1,216 1,285 1,387 1,412 14,419 1,108 4,462 25,287 1,003 834 2,046 1,429 266 66 19,643
Balance sheet still healthy  Improving ROE	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity	ecast (HK\$m) 1,300 1,136 1,223 1,337 11,971 1,281 3,174 21,422 2,514 740 1,705 3,514 223 7 12,718	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 266 66 13,181	1,099 1,162 1,292 1,412 13,453 1,164 4,462 24,044 2,379 777 2,046 3,389 266 66 15,122	1,166 1,233 1,347 1,412 13,974 1,135 4,462 24,729 1,757 810 2,046 2,503 266 66 17,282	1,216 1,285 1,387 1,412 14,419 1,108 4,462 25,287 1,003 834 2,046 1,429 266 66 19,643
	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity Ratio analysis	ecast (HK\$m) 1,300 1,136 1,223 1,337 11,971 1,281 3,174 21,422 2,514 740 1,705 3,514 223 7 12,718 21,422	2,768 1,036 1,321 1,412 11,831 1,193 4,462 24,022 3,165 789 2,046 4,509 266 66 13,181 24,022	1,099 1,162 1,292 1,412 13,453 1,164 4,462 24,044 2,379 777 2,046 3,389 266 66 15,122 24,044	1,166 1,233 1,347 1,412 13,974 1,135 4,462 24,729 1,757 810 2,046 2,503 266 66 17,282 24,729 6.1	1,216 1,285 1,387 1,412 14,419 1,108 4,462 25,287 1,003 834 2,046 1,429 266 66 19,643 25,287
	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity  Ratio analysis Revenue growth (% YoY)	ecast (HK\$m) 1,300 1,136 1,223 1,337 11,971 1,281 3,174 21,422 2,514 740 1,705 3,514 223 7 12,718 21,422	2,768 1,036 1,321 1,412 11,831 1,193 4,462 24,022 3,165 789 2,046 4,509 266 66 13,181 24,022	1,099 1,162 1,292 1,412 13,453 1,164 4,462 24,044 2,379 777 2,046 3,389 266 66 15,122 24,044	1,166 1,233 1,347 1,412 13,974 1,135 4,462 24,729 1,757 810 2,046 2,503 266 66 17,282 24,729	1,216 1,285 1,387 1,412 14,419 1,108 4,462 25,287 1,003 834 2,046 1,429 266 66 19,643 25,287
	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity  Ratio analysis Revenue growth (% YoY) Ebitda growth (% YoY)	ecast (HK\$m) 1,300 1,136 1,223 1,337 11,971 1,281 3,174 21,422 2,514 740 1,705 3,514 223 7 12,718 21,422 5.5 33.0	2,768 1,036 1,321 1,412 11,831 1,193 4,462 24,022 3,165 789 2,046 4,509 266 66 13,181 24,022	1,099 1,162 1,292 1,412 13,453 1,164 4,462 24,044 2,379 777 2,046 3,389 266 66 15,122 24,044  7.0 19.9	1,166 1,233 1,347 1,412 13,974 1,135 4,462 24,729 1,757 810 2,046 2,503 266 66 17,282 24,729 6.1 11.5	1,216 1,285 1,387 1,412 14,419 1,108 4,462 25,287 1,003 834 2,046 1,429 266 66 19,643 25,287 4.2 7.8
	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity  Ratio analysis Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%)	ecast (HK\$m) 1,300 1,136 1,223 1,337 11,971 1,281 3,174 21,422 2,514 740 1,705 3,514 223 7 12,718 21,422 5.5 33.0 20.2	2,768 1,036 1,321 1,412 11,831 1,193 4,462 24,022 3,165 789 2,046 4,509 266 66 13,181 24,022	1,099 1,162 1,292 1,412 13,453 1,164 4,462 24,044 2,379 777 2,046 3,389 266 66 15,122 24,044  7.0 19.9 32.0	1,166 1,233 1,347 1,412 13,974 1,135 4,462 24,729 1,757 810 2,046 2,503 266 66 17,282 24,729 6.1 11.5 33.6	1,216 1,285 1,387 1,412 14,419 1,108 4,462 25,287 1,003 834 2,046 1,429 266 66 19,643 25,287 4.2 7.8 34.7
	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity  Ratio analysis Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%) Net profit margin (%)	ecast (HK\$m) 1,300 1,136 1,223 1,337 11,971 1,281 3,174 21,422 2,514 740 1,705 3,514 223 7 12,718 21,422 5.5 33.0 20.2 18.4	2,768 1,036 1,321 1,412 11,831 1,193 4,462 24,022 3,165 789 2,046 4,509 266 66 13,181 24,022  12.1 58.4 28.5 25.0	1,099 1,162 1,292 1,412 13,453 1,164 4,462 24,044 2,379 777 2,046 3,389 266 66 15,122 24,044  7.0 19.9 32.0 27.3	1,166 1,233 1,347 1,412 13,974 1,135 4,462 24,729 1,757 810 2,046 2,503 266 66 17,282 24,729 6.1 11.5 33.6 28.7	1,216 1,285 1,387 1,412 14,419 1,108 4,462 25,287 1,003 834 2,046 1,429 266 66 19,643 25,287 4.2 7.8 34.7 30.1
	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity  Ratio analysis Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%) Net profit margin (%) Dividend payout (%)	ecast (HK\$m) 1,300 1,136 1,223 1,337 11,971 1,281 3,174 21,422 2,514 740 1,705 3,514 223 7 12,718 21,422  5.5 33.0 20.2 18.4 50.5	2,768 1,036 1,321 1,412 11,831 1,193 4,462 24,022 3,165 789 2,046 4,509 266 66 13,181 24,022  12.1 58.4 28.5 25.0 49.7	1,099 1,162 1,292 1,412 13,453 1,164 4,462 24,044 2,379 777 2,046 3,389 266 66 15,122 24,044 7.0 19.9 32.0 27.3 49.7	1,166 1,233 1,347 1,412 13,974 1,135 4,462 24,729 1,757 810 2,046 2,503 266 66 17,282 24,729 6.1 11.5 33.6 28.7 49.7	1,216 1,285 1,387 1,412 14,419 1,108 4,462 25,287 1,003 834 2,046 1,429 266 66 19,643 25,287  4.2 7.8 34.7 30.1 49.7
	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity  Ratio analysis Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%) Net profit margin (%) Dividend payout (%) Effective tax rate (%)	ecast (HK\$m) 1,300 1,136 1,223 1,337 11,971 1,281 3,174 21,422 2,514 740 1,705 3,514 223 7 12,718 21,422  5.5 33.0 20.2 18.4 50.5 11.2 46.1 37.2	2,768 1,036 1,321 1,412 11,831 1,193 4,462 24,022 3,165 789 2,046 4,509 266 66 13,181 24,022  12.1 58.4 28.5 25.0 49.7 15.9	1,099 1,162 1,292 1,412 13,453 1,164 4,462 24,044 2,379 777 2,046 3,389 266 66 15,122 24,044  7.0 19.9 32.0 27.3 49.7 14.8	1,166 1,233 1,347 1,412 13,974 1,135 4,462 24,729 1,757 810 2,046 2,503 266 66 17,282 24,729 6.1 11.5 33.6 28.7 49.7 14.7 110.0 17.8	1,216 1,285 1,387 1,412 14,419 1,108 4,462 25,287 1,003 834 2,046 1,429 266 66 19,643 25,287  4.2 7.8 34.7 30.1 49.7 14.6
	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity  Ratio analysis Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%) Net profit margin (%) Dividend payout (%) Effective tax rate (%) Ebitda/net int exp (x) Net debt/equity (%) ROE (%)	ecast (HK\$m) 1,300 1,136 1,223 1,337 11,971 1,281 3,174 21,422 2,514 740 1,705 3,514 223 7 12,718 21,422  5.5 33.0 20.2 18.4 50.5 11.2 46.1 37.2 16.9	2,768 1,036 1,321 1,412 11,831 1,193 4,462 24,022 3,165 789 2,046 4,509 266 66 13,181 24,022  12.1 58.4 28.5 25.0 49.7 15.9 47.7 37.0 24.8	1,099 1,162 1,292 1,412 13,453 1,164 4,462 24,044 2,379 777 2,046 3,389 266 66 15,122 24,044  7.0 19.9 32.0 27.3 49.7 14.8 104.3 30.7 26.6	1,166 1,233 1,347 1,412 13,974 1,135 4,462 24,729 1,757 810 2,046 2,503 266 66 17,282 24,729 6.1 11.5 33.6 28.7 49.7 110.0 17.8 25.8	1,216 1,285 1,387 1,412 14,419 1,108 4,462 25,287 1,003 834 2,046 1,429 266 66 19,643 25,287 4.2 7.8 34.7 30.1 49.7 14.6 616.8 6.2 24.7
	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity  Ratio analysis Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%) Net profit margin (%) Dividend payout (%) Effective tax rate (%) Ebitda/net int exp (x) Net debt/equity (%) ROE (%) ROIC (%)	ecast (HK\$m) 1,300 1,136 1,223 1,337 11,971 1,281 3,174 21,422 2,514 740 1,705 3,514 223 7 12,718 21,422  5.5 33.0 20.2 18.4 50.5 11.2 46.1 37.2 16.9 8.7	2,768 1,036 1,321 1,412 11,831 1,193 4,462 24,022 3,165 789 2,046 4,509 266 66 13,181 24,022  12.1 58.4 28.5 25.0 49.7 15.9 47.7 37.0 24.8 15.7	1,099 1,162 1,292 1,412 13,453 1,164 4,462 24,044 2,379 777 2,046 3,389 266 66 15,122 24,044  7.0 19.9 32.0 27.3 49.7 14.8 104.3 30.7 26.6 18.6	1,166 1,233 1,347 1,412 13,974 1,135 4,462 24,729 1,757 810 2,046 2,503 266 66 17,282 24,729 6.1 11.5 33.6 28.7 49.7 14.7 110.0 17.8 25.8 19.3	1,216 1,285 1,387 1,412 14,419 1,108 4,462 25,287 1,003 834 2,046 1,429 266 66 19,643 25,287 4.2 7.8 34.7 30.1 49.7 14.6 616.8 6.2
	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity  Ratio analysis Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%) Net profit margin (%) Dividend payout (%) Effective tax rate (%) Ebitda/net int exp (x) Net debt/equity (%) ROE (%)	ecast (HK\$m) 1,300 1,136 1,223 1,337 11,971 1,281 3,174 21,422 2,514 740 1,705 3,514 223 7 12,718 21,422  5.5 33.0 20.2 18.4 50.5 11.2 46.1 37.2 16.9	2,768 1,036 1,321 1,412 11,831 1,193 4,462 24,022 3,165 789 2,046 4,509 266 66 13,181 24,022  12.1 58.4 28.5 25.0 49.7 15.9 47.7 37.0 24.8	1,099 1,162 1,292 1,412 13,453 1,164 4,462 24,044 2,379 777 2,046 3,389 266 66 15,122 24,044  7.0 19.9 32.0 27.3 49.7 14.8 104.3 30.7 26.6	1,166 1,233 1,347 1,412 13,974 1,135 4,462 24,729 1,757 810 2,046 2,503 266 66 17,282 24,729 6.1 11.5 33.6 28.7 49.7 110.0 17.8 25.8	1,216 1,285 1,387 1,412 14,419 1,108 4,462 25,287 1,003 834 2,046 1,429 266 66 19,643 25,287 4.2 7.8 34.7 30.1 49.7 14.6 616.8 6.2 24.7

**28 February 2017** 

Source: CLSA





### **Research subscriptions**

To change your report distribution requirements, please contact your CLSA sales representative or email us at cib@clsa.com. You can also fine-tune your Research Alert email preferences at https://www.clsa.com/member/tools/email\_alert/.

### **Companies mentioned**

Xinyi Glass (868 HK - HK\$7.04 - BUY) Asahi Glass (5201 JP - ¥918 - BUY) AVIC Sanxin (N-R) Central Glass (N-R) Changzhou Almaden (N-R) China Glass (N-R) Cie de St-Gobain (N-R) Corning (N-R) CSG - A (N-R) Fuyao Glass - A (N-R) Fuyao Glass (N-R) Hankuk Glass Ind (N-R) Jinjing (N-R) Kibing (N-R) Luoyang Glass (N-R) NSG (N-R) PPG (N-R) Sise Cam (N-R) SYP Glass - A (N-R) Taiwan Glass (N-R) Trakya Cam Sanayii (N-R) Xinyi Solar (968 HK - HK\$2.73 - BUY) Xiuqiang Glasswork (N-R)

### **Analyst certification**

The analyst(s) of this report hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this research report.



### **Important disclosures**

Recommendation history of Xinyi Glass Holdings Ltd 868 HK




May 14 Sep 14 Jan 15 May 15 Sep 15 Jan 16 May 16 Sep 16 Jan 17

Date	Rec	Target	Date	Rec	Target
14 Dec 2016	BUY	8.35	29 Jul 2015	O-PF	4.24*
08 Nov 2016	BUY	8.30	24 Apr 2015	O-PF	4.90*
08 Sep 2016	BUY	8.35	03 Mar 2015	O-PF	4.81*
03 Aug 2016	BUY	7.25	10 Dec 2014	O-PF	4.23*
15 Jun 2016	O-PF	6.12*	25 Sep 2014	O-PF	5.28*
04 May 2016	O-PF	5.56*	24 Jul 2014	O-PF	4.85*
16 Mar 2016	O-PF	4.80*	25 Jun 2014	O-PF	4.95*
05 Feb 2016	O-PF	4.24*	23 May 2014	BUY	6.31*
19 Nov 2015	O-PF	4.33*			

Source: CLSA; \* Adjusted for corporate action








May 14 Sep 14 Jan 15 May 15 Sep 15 Jan 16 May 16 Sep 16 Jan 17

Date	Rec	Target	Date	Rec	Target
28 Feb 2017	BUY	3.40	12 Jun 2015	BUY	4.58
14 Dec 2016	BUY	3.50	27 May 2015	BUY	4.10
18 Oct 2016	BUY	3.90	24 Apr 2015	BUY	3.59
15 Jun 2016	BUY	4.20	12 Mar 2015	BUY	3.13
16 Mar 2016	BUY	4.00	04 Dec 2014	BUY	3.27
05 Feb 2016	BUY	4.10	25 Sep 2014	BUY	3.20
12 Jan 2016	BUY	4.60	24 Jul 2014	BUY	2.76
19 Nov 2015	BUY	4.70	25 Jun 2014	BUY	2.50
02 Nov 2015	BUY	4.60	23 Apr 2014	BUY	2.63
19 Oct 2015	BUY	4.70			

Source: CLSA

### Recommendation history of Asahi Glass Co Ltd 5201 JP



Date	Rec	Target	Date	Rec	Target
07 Feb 2017	BUY	1,025.00	17 May 2016	O-PF	750.00
31 Oct 2016	O-PF	780.00	09 May 2016	U-PF	710.00
06 Sep 2016	BUY	780.00	05 Feb 2016	U-PF	740.00
01 Aug 2016	BUY	750.00	20 Oct 2015	BUY	860.00

Source: CLSA

The policy of CLSA (which for the purpose of this disclosure includes subsidiaries of CLSA B.V. and CLSA  $\,$ 

Americas, LLC ("CLSA Americas")), and CL Securities Taiwan Co., Ltd. ("CLST") is to only publish research that



is impartial, independent, clear, fair, and not misleading. Analysts may not receive compensation from the companies they cover. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to a research report as below. This research disclosure should be read in conjunction with the research disclaimer as set out at www.clsa.com/disclaimer.html and the regulation of the concerned market where the analyst is stationed and hence subject to. This research disclosure is for your information only and does not constitute any recommendation, representation or warranty. Absence of discloseable position should not be taken as endorsement on the validity or quality of the research report or recommendation.

To maintain the independence and integrity of CLSA's research, our Corporate Finance, Sales Trading and Research business lines are distinct from one another. This means that CLSA's Research department is not part of and does not report to CLSA Corporate Finance (or "investment banking") department or CLSA's Sales and Trading business. Accordingly, neither the Corporate Finance nor the Sales and Trading department supervises or controls the activities of CLSA's research analysts. CLSA's research analysts report to the management of the Research department, who in turn report to CLSA's senior management.

CLSA has put in place a number of internal controls designed to manage conflicts of interest that may arise as a result of CLSA engaging in Corporate Finance, Sales and Trading and Research activities. Some examples of these controls include: the use of information barriers and other information controls designed to ensure that confidential information is only shared on a "need to know" basis and in compliance with CLSA's Chinese Wall policies and procedures; measures designed to ensure that interactions that may occur among CLSA's Research personnel, Corporate Finance and Sales and Trading personnel, CLSA's financial product issuers and CLSA's research analysts do not compromise the integrity and independence of CLSA's research.

Neither analysts nor their household members/associates/may have a financial interest in, or be an officer, director or advisory board member of companies covered by the analyst unless disclosed herein. In circumstances where an analyst has a pre-existing holding in any securities under coverage, those holdings are grandfathered and the analyst is prohibited from trading such securities.

Unless specified otherwise, CLSA/CLSA Americas/CLST did not receive investment banking/non-

investment banking income from, and did not manage/co-manage a public offering for, the listed company during the past 12 months, and it does not expect to receive investment banking compensation from the listed company within the coming three months. Unless mentioned otherwise, CLSA/CLSA Americas/CLST does not own a material discloseable position, and does not make a market, in the securities.

As analyst(s) of this report, I/we hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this report or to any investment banking relationship with the subject company covered in this report (for the past one year) or otherwise any other relationship with such company which leads to receipt of fees from the company except in ordinary course of business of the company. The analyst/s also state/s and confirm/s that he/she/they has/have not been placed under any undue influence, intervention or pressure by any person/s in compiling this research report. In addition, the analysts included herein attest that they were not in possession of any material, nonpublic information regarding the subject company at the time of publication of the report. Save from the disclosure below (if any), the analyst(s) is/are not aware of any material conflict of interest.

Key to CLSA/CLSA Americas/CLST investment rankings: BUY: Total stock return (including dividends) expected to exceed 20%; O-PF: Total expected return below 20% but exceeding market return; U-PF: Total expected return positive but below market return; SELL: Total return expected to be negative. For relative performance, we benchmark the 12-month total forecast return (including dividends) for the stock against the 12-month forecast return (including dividends) for the market on which the stock trades.

In the case of US stocks, the recommendation is relative to the expected return for the S&P500 of 10%. Exceptions may be made depending upon prevailing market conditions. We define as "Double Baggers" stocks we expect to yield 100% or more (including dividends) within three years at the time the stocks are introduced to our "Double Bagger" list. "High Conviction" Ideas are not necessarily stocks with the most upside/downside, but those where the Research Head/Strategist believes there is the highest likelihood of positive/negative returns. The list for each market is monitored weekly.

Overall rating distribution for CLSA/CLSA Americas only /CLST only Universe:



Overall rating distribution: Buy / Outperform - CLSA: 61.61%; CLSA Americas only: 54.55%; CLST only: 71.62%, Underperform / Sell - CLSA: 38.39%; CLSA Americas only: 45.45%; CLST only: 28.38%, Restricted - CLSA: 0.00%; CLSA Americas only: 0.00%; CLST only: 0.00%. Data as of 31 December 2016.

Investment banking clients as a % of rating category: Buy / Outperform - CLSA: 3.55%; CLSA Americas only: 0.00%; CLST only: 0.00%, Underperform / Sell - CLSA: 2.85%; CLSA Americas only: 0.00%; CLST only: 0.00%, Restricted - CLSA: 0.00%; CLSA Americas only: 0.00%; CLST only: 0.00% . Data for 12-month period ending 31 December 2016.

There are no numbers for Hold/Neutral as CLSA/CLSA Americas/CLST do not have such investment rankings.

For a history of the recommendations and price targets for companies mentioned in this report, as well as company specific disclosures, please write to: (a) CLSA Americas, Compliance Department, 1301 Avenue of the Americas, 15th Floor, New York, New York 10019-6022; (b) CLSA, Group Compliance, 18/F, One Pacific Place, 88 Queensway, Hong Kong and/or; (c) CLST Compliance (27/F, 95, Section 2 Dun Hua South Road, Taipei 10682, Taiwan, telephone (886) 2 2326 8188). © 2017 CLSA Limited, CLSA Americas, and/or CLST.

© 2017 CLSA Limited, CLSA Americas, LLC ("CLSA Americas") and/or CL Securities Taiwan Co., Ltd. ("CLST")

This publication/communication is subject to and incorporates the terms and conditions of use set out on www.clsa.com website (www.clsa.com/disclaimer.html.). the Neither publication/communication nor any portion hereof may resold, reproduced, reprinted, sold, copied, distributed, redistributed, published, republished, displayed, posted or transmitted in any form or media or by any means without the written consent of CLSA group of companies (excluding CLSA Americas, LLC) ("CLSA"), CLSA Americas (a broker-dealer registered with the US Securities and Exchange Commission and an affiliate of CLSA) and/or CLST.

CLSA, CLSA Americas and CLST has/have produced this publication/communication for private circulation to professional, institutional and/or wholesale clients only. This publication/communication may not be distributed or redistributed to retail investors. The information, opinions and estimates herein are not directed at, or intended for distribution to or use by, any person or entity in any jurisdiction where doing so would be contrary to law or regulation or which would subject CLSA, CLSA Americas

and/or CLST to any additional registration or licensing requirement within such jurisdiction. The information and statistical data herein have been obtained from sources we believe to be reliable. Such information has not been independently verified and we make no representation or warranty as to its accuracy, completeness or correctness. Any opinions or estimates herein reflect the judgment of CLSA, CLSA Americas and/or CLST at the date of this publication/communication and are subject to change at any time without notice. Where any part of the information, opinions or estimates contained herein reflects the views and opinions of a sales person or a non-analyst, such views and opinions may not correspond to the published view of CLSA, CLSA Americas and/or CLST. This is not a solicitation or any offer to buy or sell. This publication/communication is for information purposes only and does not constitute any recommendation, representation, warranty or guarantee of performance. Any price target given in the report may be projected from one or more valuation models and hence any price target may be subject to the inherent risk of the selected model as well as other external risk factors. This is not intended to provide professional, investment or any other type of advice recommendation and does not take into account the particular investment objectives, financial situation or needs of individual recipients. Before acting on any information in this publication/communication, you should consider whether it is suitable for your particular circumstances and, if appropriate, seek professional advice, including tax advice. CLSA, CLSA Americas and/or CLST do/does not accept any responsibility and cannot be held liable for any person's use of or reliance on the information and opinions contained herein. To the extent permitted by applicable securities laws and regulations, CLSA, CLSA Americas and/or CLST accept(s) no liability whatsoever for any direct or consequential loss arising from the use of this publication/communication or its contents. Where the publication does not contain ratings, the material should not be construed as research but is offered as factual commentary. It is not intended to, nor should it be used to form an investment opinion about the non-rated companies.

Subject to any applicable laws and regulations at any given time, CLSA, CLSA Americas, CLST, their respective affiliates or companies or individuals connected with CLSA/CLSA Americas/CLST may have used the information contained herein before publication and may have positions in, may from time to time purchase or sell or have a material interest in any of the securities mentioned or related securities, or may currently or in future have or have had a business or financial relationship with, or may provide or have provided investment banking, capital markets and/or other



services to, the entities referred to herein, their advisors and/or any other connected parties. As a result, investors should be aware that CLSA, CLSA Americas, CLST and/or their respective affiliates or companies or such individuals may have one or more conflicts of interest. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to research reports. Details of the disclosable interest can be found in certain reports as required by the relevant rules and regulation and the full details are available at http://www.clsa.com/member/research\_disclosures/. Disclosures therein include the position of CLSA, CLSA Americas and CLST only. Unless specified otherwise, CLSA did not receive any compensation or other benefits from subject company covered this publication/communication.. If investors have accessing this website, please contact webadmin@clsa.com on +852 2600 8111. If you require disclosure information on previous dates, please contact compliance\_hk@clsa.com.

This publication/communication is distributed for and on behalf of CLSA Limited (for research compiled by non-US and non-Taiwan analyst(s)), CLSA Americas (for research compiled by US analyst(s)) and/or CLST (for research compiled by Taiwan analyst(s)) in Australia by CLSA Australia Pty Ltd; in Hong Kong by CLSA Limited; in India by CLSA India Private Limited, (Address: 8/F, Dalamal House, Nariman Point, Mumbai 400021. Tel No: +91-22-66505050. Fax No: +91-22-22840271; CIN: U67120MH1994PLC083118; SEBI Registration INZ000001735; in Indonesia by PT CLSA Sekuritas Indonesia; in Japan by CLSA Securities Japan Co., Ltd; in Korea by CLSA Securities Korea Ltd; in Malaysia by CLSA Securities Malaysia Sdn Bhd; in the Philippines by CLSA Philippines Inc (a member of Philippine Stock Exchange and Securities Investors Protection Fund); in Thailand by CLSA Securities (Thailand) Limited; in Taiwan by CLST and in United Kingdom by CLSA (UK).

India: CLSA India Private Limited, incorporated in November 1994 provides equity brokerage services (SEBI Registration No: INZ000001735), research services (SEBI Registration No: INH000001113) and merchant banking services (SEBI Registration No.INM000010619) to global institutional investors, pension funds and corporates. CLSA and its associates may have debt holdings in the subject company. Further, CLSA and its associates, in the past 12 months, may have received compensation for non-investment banking securities and/or non-securities related services from the subject company. For further details of "associates" of CLSA India please contact Compliance-India@clsa.com.

United States of America: Where any section of the research is compiled by US analyst(s), it is distributed by CLSA Americas. Where any section is compiled by non-US analyst(s), it is distributed into the United States by CLSA solely to persons who qualify as "Major US Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934 and who deal with CLSA Americas. However, the delivery of this research report to any person in the United States shall not be deemed a recommendation to effect any transactions in the securities discussed herein or an endorsement of any opinion expressed herein. Any recipient of this research in the United States wishing to effect a transaction in any security mentioned herein should do so by contacting CLSA Americas.

Canada: The delivery of this research report to any person in Canada shall not be deemed a recommendation to effect any transactions in the securities discussed herein or an endorsement of any opinion expressed herein. Any recipient of this research in Canada wishing to effect a transaction in any security mentioned herein should do so by contacting CLSA Americas.

United Kingdom: In the United Kingdom, this research is a marketing communication. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research, and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The research is disseminated in the EU by CLSA (UK), which is authorised and regulated by the Financial Conduct Authority. This document is directed at persons having professional experience in matters relating to investments as defined in Article 19 of the FSMA 2000 (Financial Promotion) Order 2005. Any investment activity to which it relates is only available to such persons. If you do not have professional experience in matters relating investments you should not rely on this document. Where the research material is compiled by the UK analyst(s), it is produced and disseminated by CLSA (UK). For the purposes of the Financial Conduct Rules this research is prepared and intended as substantive research material.

Singapore: In Singapore, research is issues and/or distributed by CLSA Singapore Pte Ltd (Company Registration No.: 198703750W), a Capital Markets Services license holder to deal in securities and an exempt financial adviser, a solely to persons who qualify as an institutional investor, accredited investor or expert investor, as defined in s.4A(1) of the Securities and Futures Act. Pursuant to Paragraphs 33, 34, 35 and 36 of the Financial Advisers (Amendment) Regulations 2005 of



the Financial Advisers Act (Cap 110) with regards to an institutional investor, accredited investor expert investor or Overseas Investor, sections 25, 27 and 36 of the Financial Adviser Act (Cap 110) shall not apply to CLSA Singapore Pte Ltd. Please contact CLSA Singapore Pte Ltd (telephone No.: +65 6416 7888) in connection with queries on the report. MCI (P) 033/11/2016

The analysts/contributors to this publication/communication may be employed by any relevant CLSA entity (including CLSA Americas), CLST or a subsidiary of CITIC Securities Company Limited which is different from the entity that distributes the publication/communication in the respective jurisdictions.

MSCI-sourced information is the exclusive property of Morgan Stanley Capital International Inc (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, redisseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the

entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are service marks of MSCI and its affiliates. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and Standard & Poor's. GICS is a service mark of MSCI and S&P and has been licensed for use by CLSA.

EVA® is a registered trademark of Stern, Stewart & Co. "CL" in charts and tables stands for CLSA/CLSA Americas and "CT" stands for CLST estimates unless otherwise noted in the source.